Jim Cramer on Biohaven: "The Stock Seems Very Low to Me"

Biohaven Ltd. (NYSE:BHVN) is one of the stocks Jim Cramer recently shed light on. During the lightning round, when a caller inquired about the stock, Cramer stated:

“Okay, well, I’ll tell you in full disclosure, I have a deal with Biohaven over a drug that I’ve invented with a doctor. So I will tell you the stock seems very low to me. But then again, because I do have that deal, you might just say, well, wait a second, Cramer’s, you know, how can you tell? But boy, is it low.”

Biohaven Ltd. (NYSE:BHVN) develops treatments for neurological, psychiatric, autoimmune, and cancer-related conditions, with several drugs in clinical trials. A caller asked about the stock during the May 29 episode, and Cramer responded:

“Alright, Biohaven had an analyst day the other day, and it was, you know, people didn’t get excited about it. Now, in full disclosure, I do have a personal deal with Biohaven, and I don’t talk about it much because it’s not been disclosed, but I am surprised this stock is all the way down here. Vlad Coric is really good. I think that this is a buy, but you could say, hey Cramer, you’re biased, you got a deal with them. But I’m just telling you that’s how I feel, or else I wouldn’t have a deal with them.”

While we acknowledge the potential of BHVN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.